Biomotion Sciences Ordinary Shares Cash Flow Conversion Efficiency
Biomotion Sciences Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has a cash flow conversion efficiency ratio of -66.477x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($44.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biomotion Sciences Ordinary Shares (2020–2025)
Cash flow conversion efficiency of Biomotion Sciences Ordinary Shares from 2020 to 2025. This chart illustrates how Biomotion Sciences Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SLXN live share price for real-time trading data and today's change.
Biomotion Sciences Ordinary Shares Cash Flow Conversion Ratio Explained
Biomotion Sciences Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biomotion Sciences Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their cash flow conversion efficiency. Also see Biomotion Sciences Ordinary Shares stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Portofino Resources Inc
V:POR
|
0.012x |
|
FINEQIA INTERN. INC. O.N.
F:FNQA
|
0.125x |
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
-0.136x |
|
E2Gold Inc
V:ETU
|
0.011x |
|
Lucibel
PA:ALUCI
|
6.802x |
|
Yolo SA
WAR:YOL
|
0.005x |
|
Maison Solutions Inc
NASDAQ:MSS
|
0.205x |
|
Sentul City Tbk
JK:BKSL
|
0.030x |
Annual Cash Flow Conversion Efficiency for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Biomotion Sciences Ordinary Shares from 2020 to 2025. Review Biomotion Sciences Ordinary Shares (SLXN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.60 Million | $-10.82 Million | -4.156x | -297.47% |
| 2024-12-31 | $-3.99 Million | $-8.40 Million | 2.105x | +460.29% |
| 2023-12-31 | $-12.06 Million | $-4.53 Million | 0.376x | -20.26% |
| 2022-12-31 | $-7.08 Million | $-3.33 Million | 0.471x | +3946.78% |
| 2021-12-31 | $114.91 Million | $-1.41 Million | -0.012x | -102.78% |
| 2020-12-31 | $-169.99K | $-75.00K | 0.441x | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more